The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has announced new antidepressant safety measures that expand suicide-risk information to patients of all ages and, for the first time, recognize Post-SSRI Sexual Dysfunction (PSSD) as a risk that can persist after treatment stops. The move has prompted Citizens Commission on Human Rights International (CCHR), a mental health industry watchdog, to urge the U.S. Food and Drug Administration to issue equivalent warnings. The announcement matters because it widens the scope of acknowledged risk beyond the narrow age bands that have governed U.S. labeling for two decades, and because it formally links certain antidepressants to sexual side effects that may not resolve after discontinuation.
The regulatory divergence is not new. In December 2003, the MHRA became the first regulator to warn that SSRI antidepressants increased suicide and self-harm risk in young people, acting on concerns raised by Dr. David Healy, professor of psychiatry at Bangor University. The FDA added a black-box warning for suicidal ideation in patients aged 18 and younger in October 2004, almost a year later, and later extended it to age 24, leaving the implication that the risk ends at 25. CCHR points out that the FDA had relevant data for decades, including a 1985 memo from the manufacturer of fluoxetine reporting a suicide rate 5.6 times higher than for older tricyclic antidepressants. In 1991, CCHR helped secure an FDA advisory committee hearing into antidepressants causing suicidal ideation and violent behavior, but the panel negated the risks.
The UK measures now require healthcare professionals to discuss suicide risk and persistent sexual dysfunction when starting antidepressants, changing doses, or reviewing treatment. Patient information leaflets for citalopram, escitalopram, duloxetine, fluvoxamine, fluoxetine, paroxetine, sertraline, venlafaxine, amitriptyline, and nortriptyline will carry prominent boxed warnings. Symptoms of PSSD include genital numbness, loss of libido, erectile dysfunction, and difficulty reaching orgasm. "Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions," said Dr. Alison Cave, chief safety officer at the MHRA.
The implications for U.S. patients are substantial. According to the IQVia Total Patient Tracker Database for 2020, 45,204,771 Americans were taking antidepressants, including 2,154,118 in the 0-17 age group. Other regulators have already acted: the European Medicines Agency adopted product information updates in 2019 warning of long-lasting sexual dysfunction, and Health Canada completed a safety review and announced labeling updates in 2021. The FDA has not issued class-wide labeling to match a 2018 citizen petition by Healy and 22 international experts seeking prominent warnings that these drugs can reduce genital sensitivity, sometimes within 30 minutes of the first dose, with effects that may last for years or indefinitely. CCHR argues that until the FDA aligns U.S. labeling with the MHRA's measures, millions of Americans are taking these drugs without the full safety disclosures now required elsewhere.
